Roberta D Brinton
Overview
Explore the profile of Roberta D Brinton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
2402
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mauvais-Jarvis F, Merz N, Barnes P, Brinton R, Carrero J, DeMeo D, et al.
Lancet
. 2020 Aug;
396(10250):565-582.
PMID: 32828189
Clinicians can encounter sex and gender disparities in diagnostic and therapeutic responses. These disparities are noted in epidemiology, pathophysiology, clinical manifestations, disease progression, and response to treatment. This Review discusses...
12.
Cunnane S, Trushina E, Morland C, Prigione A, Casadesus G, Andrews Z, et al.
Nat Rev Drug Discov
. 2020 Jul;
19(9):609-633.
PMID: 32709961
The brain requires a continuous supply of energy in the form of ATP, most of which is produced from glucose by oxidative phosphorylation in mitochondria, complemented by aerobic glycolysis in...
13.
Rahman A, Schelbaum E, Hoffman K, Diaz I, Hristov H, Andrews R, et al.
Neurology
. 2020 Jun;
95(2):e166-e178.
PMID: 32580974
Objective: To investigate sex differences in late-onset Alzheimer disease (AD) risks by means of multimodality brain biomarkers (β-amyloid load via C-Pittsburgh compound B [PiB] PET, neurodegeneration via F-fluorodeoxyglucose [FDG] PET...
14.
Cable J, Holtzman D, Hyman B, Tansey M, Colonna M, Kellis M, et al.
Ann N Y Acad Sci
. 2020 May;
1475(1):3-14.
PMID: 32472577
For decades, Alzheimer's disease research has focused on amyloid as the primary pathogenic agent. This focus has driven the development of numerous amyloid-targeting therapies; however, with one possible exception, none...
15.
Arnold M, Nho K, Kueider-Paisley A, Massaro T, Huynh K, Brauner B, et al.
Nat Commun
. 2020 Mar;
11(1):1148.
PMID: 32123170
Late-onset Alzheimer's disease (AD) can, in part, be considered a metabolic disease. Besides age, female sex and APOE ε4 genotype represent strong risk factors for AD that also give rise...
16.
Karim R, Dang H, Hodis H, Stanczyk F, Brinton R, Mack W
Menopause
. 2020 Feb;
27(5):512-518.
PMID: 32049929
Objective: Vasomotor flushing (hot flushes) is a common menopausal symptom experienced by most women going through the menopausal transition; flushing continues for a variable period in postmenopause. Primarily due to...
17.
Shang Y, Mishra A, Wang T, Wang Y, Desai M, Chen S, et al.
PLoS One
. 2020 Jan;
15(1):e0225392.
PMID: 31917799
Late onset Alzheimer's disease (LOAD) is a progressive neurodegenerative disease with four well-established risk factors: age, APOE4 genotype, female chromosomal sex, and maternal history of AD. Each risk factor impacts...
18.
Wang Y, Hernandez G, Mack W, Schneider L, Yin F, Brinton R
Menopause
. 2019 Oct;
27(1):57-65.
PMID: 31567873
Objective: PhytoSERM is a selective estrogen receptor beta (ERβ) modulator comprised of three phytoestrogens: genistein, daidzein, and S-equol. The PhytoSERM formulation promotes estrogenic action in the brain while largely inactive...
19.
Schneider L, Hernandez G, Zhao L, Franke A, Chen Y, Pawluczyk S, et al.
Menopause
. 2019 Mar;
26(8):874-884.
PMID: 30889096
Objective: PhytoSERM is a formulation of genistein, daidzein, and S-equol that has an 83-fold selective affinity for estrogen receptor-β (ERβ); and may enhance neuron function and estrogenic mechanisms in the...
20.
Mishra A, Brinton R
Front Aging Neurosci
. 2018 Oct;
10:312.
PMID: 30356809
Neuro-inflammatory processes that contribute to development of Alzheimer's are evident early in the latent prodromal phase and worsen during the course of the disease. Despite substantial mechanistic and clinical evidence...